

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet 1 of 3				Attorney Docket Number MERCK-2593-R1-C1	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
S.T.	A1	3,979,520		ROTHE et al.	09/1976
	A2	6,544,564		FARLEY	04/2003
	A3	5,922,769		BARELLI et al.	07/1999
	A4	5,965,584		IKEDA et al.	10/1999
	A5	5,663,198		REUL et al.	09/1997
	A6	5,631,224		EFENDIC et al.	05/1997
	A7	4,916,163		NI	04/1990
	A8	4,060,634		ROTHE et al.	11/1997
S.T.	A9	3,174,901		STERNE	03/1965

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
S.T.	B1	WO	97/17975		BARELLI et al.	05/1997		
S.T.	B2	WO	98/57634		Smith et al.	12/1998		
S.T.	B3	WO	97/17975			05/1997		
	B4	DE	0 362 703			04/1998		

Examiner Signature	S.T.	Date Considered	12/21/04
-----------------------	------	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	March 25, 2004
		First Named Inventor	Yves BONHOMME et al.
		Group Art Unit	1615
		Examiner Name	Susan T. TRAN
		Attorney Docket Number	MERCK-2593-R1-C1
Sheet	2	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S.T	C1	Bi-Euglucon M Italian Package Insert, Repertorio Farmaceutico Italiano, 1998 (with English translation pp. 1-9)	
	C2	R. Vigneri, et al., Diabete & Metabolisme, vol. 17, pp. 232-234, "Treatment of NIDDM Patients With Secondary Failure to Glyburide: Comparison of the Addition of Either Metformin or Bed-Time NPH Insulin to Glyburide", 1991	
	C3	Linda Higginbotham, et al., The Medical Journal of Australia, pp. 154-156, "Double-Blind Trial of Metformin in the Therapy of Non-Ketotic Diabetics", Aug. 11, 1979	
	C4	Iris J. Edwards, et al., Diabetes, vol. 46, No. 5, Suppl. 1, pp. 45A, "Combination Glipizide Gits/Metformin Treatment Reduces Low Density Lipoprotein Binding To Arterial Proteoglycans In NIDDM", 1997	
	C5	William T. Cefalu, et al., Diabetes, vol. 45, Suppl. 2, pp. 201A, "Combination Glipizide Gits/Metformin Normalizes Glucose And Improves Insulin Sensitivity In Hyperinsulinemic Moderately Well Controlled NIDDM", 1996	
	C6	John R. Crouse, et al., Circulation, vol. 94, No. 8, Suppl. 1508, Effects Of Combination Glipizide Gits/Metformin Treatment On Oxidizability Of LDL In Non-Insulin Dependent Diabetes Mellitus, 1996	
	C7	W. T. Cefalu, et al., Diabetologia, vol. 39, Suppl. 1, pp. A231, "Insulin Sensitivity Is Improved After Glipizide Monotherapy And Combination With Metformin", 1996	
	C8	Gerald M. Reaven, et al., Journal of Clinical Endocrinology and Metabolism, vol. 74, No. 5, pp. 1020-1026, Combined Metformin-Sulfonylurea Treatment Of Patients With Noninsulin-Dependent Diabetes In Fair To Poor Glycemic Control, 1992	
	C9	CB Hollenbeck, et al., Diabetes, vol. 39, Suppl. 1, pp. 108A, "Combination Glipizide/Metformin Treatment In Non-Insulin Dependent Diabetes (NIDDM)", 1990.	
	C10	Press Release Sep. 30, 1999: Bristol-Myers Squibb Files New Drug Application for Novel Oral Antidiabetic Drug, 2 pp., 1999.	
	C11	Glucomide--Italian Package Insert, Repertorio Farmaceutico Italiano, 1 p., 1999 (with English translation pp. 1-6).	
	C12	Glibomet--Italian Package Insert, Repertorio Farmaceutico Italiano, 1 p., 1999 (with English translation pp. 1-7).	
S.T	C13	Suguan M--Italian Package Insert, Repertorio Farmaceutico Italiano, 1 p., 1999 (with English translation pp. 1-9).	

Examiner Signature	S.T	Date Considered	12/21/04
--------------------	-----	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number		
			Filing Date	March 25, 2004	
			First Named Inventor	Yves BONHOMME et al.	
			Group Art Unit	1615	
			Examiner Name	Susan T. TRAN	
Sheet	3	of	3	Attorney Docket Number	MERCK-2593-R1-C1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C14	Bi-Euglucon M13 Italian Package Insert, Repertorio Farmaceutico Italiano, 1 p., (with English translation pp. 1-9).	
ST	C15	Blume et al., Drug Development and Industrial Pharmacy, 19(20), 2713-2741 (1993)	
	C16	PDR, 56 ed, 2002, "Alyburide" listing and Glucophage [®] and Glucovance [®] package inserts	
	C17	PDR, 52 ed, 1998, "Glyburide" listing, generic listings and Micronase [®] , Glynase [®] and Dia beta [®] package inserts	
	C18	AU 42302/89 Abstract	
ST	C19	Al-Ahmed et al., "Bioscience Reports," Vol. 9, No. 3, 1989, 347-350.	
	C20	Letter dated April 1, 2002 from Ivax Pharmaceuticals, Inc. to Lipha S.A. (assignee of U.S.P. 6,303,146) and Bristol-Myers Squibb (marketer of Glucovance[®] covered by U.S.P. 6,303,146).	

Examiner Signature	ST	Date Considered	12/21/04
--------------------	----	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.